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Abstract:
Introduction:  Endovascular thrombectomy (EVT) is a highly effective 
treatment for acute ischemic stroke due to large arterial occlusion (LAO). 
To support decisions about service provision, we previously estimated 
the annual UK population eligible for EVT as ~10% of stroke admissions. 
Since then, several trials have produced evidence that could alter these 
figures. We update our estimates considering information from studies 
and trials reporting 2018-2021 on incidence, presentation time and 
stroke severity and consider the possible impact of predicted 
demographic changes in the next 10-20 years. 
Patients and Methods: We produce an updated decision-tree describing 
the EVT eligible population for UK stroke admissions. One-way sensitivity 
analyses (using upper and lower confidence intervals for estimates at 
each branch of our decision tree) were used to identify where further 
research evidence is necessary to increase certainty around estimates 
for numbers of EVT eligible patients. 
Results: The updated estimate for the number of UK stroke patients 
eligible for EVT annually was between 10,020 (no advanced imaging in 
early presenting patients) and 9,580 (advanced imaging in all early 
presenting patients), which compared with our estimates in 2017 is a 
minimal reduction. One-way sensitivity analyses established that 
enhanced evidence about eligibility for milder strokes, ASPECTS scores 
and pre-stroke disability are offset by evidence regarding a lower 
incidence of LAO. Importantly, predicted increases in life expectancy by 
2040 may increase thrombectomy need by 40%. 
Discussion: Information from additional randomised trials published 
2018-2020 with updated estimates of LAO prevalence had a minimal 
impact on overall estimates of stroke patients eligible for EVT in the UK. 




lower ASPECTS scores has the potential to increase the estimates of the 
eligible population; future need for EVT will increase with the ageing 
population. 
Conclusion: Our updated analyses show overall numbers eligible little 
changed but evidence from ongoing trials and demographic changes 
have the potential to increase the need for EVT significantly. 
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Clinical trials show that endovascular thrombectomy (EVT) is an effective treatment for acute 
ischemic stroke causing large artery occlusion (LAO) with or without intravenous 
alteplase1,2,3,4,5,6,7,8,9,10,11 In 2016, the Highly Effective Reperfusion Evaluated in Multiple 
Endovascular Stroke trials (HERMES) individual patient meta-analysis found that for every three 
patients treated with EVT, one would have reduced disability by at least 1 level on the modified 
Rankin Scale (mRS)12.  EVT presents major challenges in many health care systems, as it is 
typically carried out by neurointerventionists with anaesthetic and other specialist staff support. It 
requires substantial imaging infrastructure: rapidly performing Computed Tomography 
Angiography (CTA), with or without advanced imaging by Perfusion-Computed Tomography 
(CTP), Magnetic Resonance imaging techniques (MR) or multiphase CTA Collateral Scoring 
(mCTA-CS) in a centralised model of hyperacute stroke care. Therefore, significant planning and 
investment is needed in most health care systems to establish capacity to deliver EVT to those 
stroke patients most likely to benefit.
In 2017 we previously estimated the UK eligible population for EVT to estimate demand and 
inform service reconfiguration and estimate the annual demand for EVT in the UK, regardless of 
geographic or service constraints such as non-existent care pathways or a lack of imaging and EVT 
facilities 13. Subsequent studies and trials (DAWN ,DEFUSE 3and Manceau et al 9,10,11) have added 
to the evidence base about patients who could benefit from EVT.  Because of the number of 
ongoing trials 14,15,16,17,18 into the effectiveness of EVT in other patient subgroups, many of which 
have been delayed by the COVID-19 pandemic, we re-examined our previous decision-tree to 
produce an updated estimate of the proportion of all stroke patients eligible for EVT. We sought to 
quantify uncertainty around key nodes in the decision-tree to enable planers to determine the effects 
of any new information on estimates of the eligible population on prevalence and effectiveness of 
EVT in sub-populations. Furthermore, we considered future stroke populations in terms of numbers 
and age profile in our sensitivity analyses looking 10-20 years ahead.
PATIENTS AND METHODS
We reviewed estimates from our previous study based on national registry data from the prospective 
Sentinel Stroke National Audit Programme (SSNAP) for England, Wales and Northern Ireland19 
and adjusted for Scotland using data from the Scottish Stroke Care Audit (SSCA)12 and produced an 
updated estimate of the number of UK patients hospitalised annually with acute stroke 15. The tree 

































































estimated eligibility by evidencing exclusions at progressive stages of the typical acute care 
pathway beginning with imaging to determine stroke type (ischaemic) followed by severity 
(National Institutes of Health Stroke Scale score; NIHSS) and time related eligibility for treatment.  
The tree then splits into early presenters and late presenters, with early presentation defined as 
within the IVT license criteria.  Eligibility in late presenters is determined using advanced imaging 
as well as clinical criteria.  In addition to clinical and CT imaging criteria, we also allowed for the 
possibility of advanced imaging for early presenters for the purpose of excluding those without 
salvageable brain tissue.  We reviewed evidence at each point in our previously published decision 
tree, updating its structure and numbers, as necessary, by expert consensus. 
One-way sensitivity analyses (using plausible intervals for our estimates at each decision point 
(node) of the decision tree) were performed to identify branches of the tree that would benefit from 
additional evidence to increase certainty around the estimates for overall eligibility. The outputs 
from these analyses are presented graphically in a tornado diagram showing the impact of numbers 
eligible for EVT as a function of the upper and lower prediction intervals for each node of the tree.  
The decision tree was created in Excel and is provided as supplementary material.
RESULTS
Review of new evidence and change to nodal decision points
The updated decision tree is presented in Figure 1. In a 2019 review into the epidemiology, natural 
history and clinical presentation of large artery stroke published in 2019, Rennert and colleagues 
estimated that the hospital incidence ranged between 28% and 40% 28. Therefore, the mean 
incidence they reported, 35%, was used in our updated tree.  This is lower than the previous 
estimate (40%) based on the earlier STOP-Stroke study 21 and the more selective HERMES trial 
meta-analysis 12.  The effect of this change was to lower the estimated eligible population, at node B 
from 33,240 to 29,080.
 
We previously estimated that (at node G), amongst early presenting (within the IVT licence 
window) moderate to severe strokes, 34% would be excluded from EVT because of clinical and/or 
imaging exclusions (originally a pre-stroke modified Rankin score (mRS) of three or more, or an 
Alberta Stroke Program Early CT Score (ASPECTS) of five or less.  Proportions of patients with an 
ASPECTS 0-5 score was based on the Interventional Management of Stroke (IMS)-3 trial CTA 
positive subgroup 22. Proportions of patients with an mRS score of three or more came from the 
STOP-Stroke study21 that identified 8.7% of LAO stroke patients with a pre-stroke mRS of 3 or 
more, which is consistent with reports from the study logs of trials included in HERMES 12. 

































































However, we update our estimates of those excluded by pre-stroke dependence to include some 
patients with a mRS of 3 because SSNAP data indicate EVT being performed on this subgroup.  
We base the percentage on the number of patients in the SSNAP national dataset treated with IVT 
who had a pre-stroke mRS of 3 with moderate or severe strokes (NIHSS ≥ 6).  These patients make 
up 0.3% of all stroke patients, or 267 patients, which represents 3% of patients at node G (early 
presenters) 23.  Evidence from DEFUSE-310 and the HERMES collaboration demonstrated the 
benefit of EVT in patients with a CT ASPECTS score of five or more.  Accordingly, we reduced 
our estimates of patients excluded at node G by 5% (3% plus 5% less 3% to allow for a known 
overlap between ASPECTS and pre-stroke mRS) from 34% to 24%, increasing the proportion 
eligible in this group. Amongst later presenters (4.5hr – 12hr), it is likely that a small number of 
patients with a pre-stroke mRS of 3 with an ASPECTS of 5 or better would be considered eligible.  
We therefore reduced, by consensus, the clinical and imaging exclusions from 75% to 72.5%. This 
results in an extra 210 late presenting patients progressing (to advanced imaging) from node K. 
Amongst the group of EVT eligible early presenting patients we had previously estimated a 5% 
spontaneous recanalization rate (node J).  Recent evidence suggests that this rate was an 
underestimate, and that 8.75% is a more accurate estimate 24.   This reduces the eligible population 
in the early-presenting group, whether advanced imaging is utilised. In the late-presenting group 
where IVT will not be administered, the 2% spontaneous recanalisation rate observed in 
DAWN/DEFUSE-3 trials.
The final piece of new evidence incorporated into our decision tree concerned patients presenting 
between 12 and 24 hours and whose eligibility must be determined by advanced imaging.  Evidence 
from DAWN would mean that an additional 5% of patients with a moderate to severe stroke would 
be eligible for EVT before any spontaneous recanalisation was accounted for in this late presenting 
group 9. Amongst DAWN participants 11.5% of patients had a moderate to severe stroke and 
overall, 5% were found eligible for EVT after advanced imaging 9. No evidence about those 
presenting between 12 and 16 hours was incorporated into our tree from DEFUSE-3 because no 
data on that specific time-period were reported and the broader eligibility criteria of ESCAPE 25 
were already incorporated in our decision tree for the group presenting at 6-12h. 
Given the complex nature of acute stroke services, to effectively plan for services estimates of 
future eligibility for EVT are required.  Like the rest of Europeans, people in the UK are living 
longer and this trend will continue over the next two decades.  The Office of National statistics 
estimate that there will be 9.9 million 75-year-olds in 2039, an increase from 5.8 million in 2019 26. 

































































Estimates of future UK stroke incidence were reported by King et al 27 who used a Delphi-style 
approach, following a review of the literature, involving experts who were aware of evidence and 
trends in stroke epidemiology. The most common estimates for increased incidence each age group 
was chosen along with the mean assumed current incidence. These estimates assume no change in 
the implementation and effectiveness of the stroke prevention management of risk factors such as 
atrial fibrillation and hypertension.
Re-estimated annual stroke patients eligible for EVT
The updated decision tree is presented in Figure 1.  The updated estimate of annual UK stroke 
admissions eligible for EVT is 9,580 to 10,020 The range is described by the use, or not, of 
advanced imaging in early presenters: 8,690 early presenters (with no use of advanced imaging) 
plus 1,330 late presenters totalling 10,020. Or 8,250 early presenters (with 100% use of advanced 
imaging) plus 1,330 late presenters totalling 9,580 This is overall a minimal reduction compared 
with our previous estimates in 2017 of between 10,440 (advanced imaging used in all early 
presenters) and 10,920 (no advanced imaging in early presenters). 
Impact of demographic trends on estimates of eligibility and impact of uncertainty around key 
parameters 
The tornado diagram (Figure 2) revealed the key nodes in the decision tree that are expected to have 
the biggest impact on plans for services.  They were estimated assuming that advanced imaging is 
not used in early presenting patients.  Node B, the proportion of LAOs in the stroke population, 
either increases or decreases the annual eligible population by 1,400 patients if the proportion is 
increased to 40% or decreased to 30% from its assumed value of 35%. If EVT is found effective in 
milder stroke (NIHSS ≤5) this would increase the numbers eligible.  Without an estimate of NIHSS 
severity of when EVT would be considered effective, we considered two scenarios.  The first when 
85% (an additional 5%) of early presenting LAO patients would be treated with an NIHSS of 5 or 
lower.  The second when 95% (an additional 10%) of early presenting LAO patients would be 
treated with an NIHSS or 5 or lower.  In these circumstances the eligible population increased by 
670 and 1,980. For later presenting patients, similar reduced exclusions by 5% and 10% to 70% and 
65% due to NHISS score (compared to the originally estimated 75%) would increase numbers by 
230 and 460 patients, respectively. Furthermore, amongst the group of early presenting patients 

































































whose NIHSS is five or lower are those who deteriorate within 24 hours. Coutts et al found that 
progression or recurrence occurred in 7% of patients presenting with NIHSS of less than four or a 
transient ischaemic attack28. Our numbers could therefore be inflated to a small extent if it were 
found that reperfusion is indicated for these patients.
Similarly, if EVT was shown to be effective in patients with ASPECT scores of 4 or less, or in 
patients with a pre-stroke disability (mRs >2), the eligible population would also increase.  At Node 
G, if the exclusion rate dropped to 25% (from 29%) an additional 490 early presenting patients 
would become eligible. If the exclusion rate dropped to 15% a further 1,700 early presenting 
patients would become eligible.  For later presenters, effectiveness of treatment with an ASPECT 
score of 4 or less would increase the eligible population by 119 if exclusion at Node K dropped 
from 75% to 70%.  If exclusion at node K dropped to 65%, then a further 350 late presenting 
patients would become eligible. 
By 2030 and 2040, these EVT eligibility estimates could increase considerably as the UK 
population ages.  These analyses (see Table 1) indicate that by 2030 there would be an additional 
24,000 patients entering our tree and an additional 49,000 by 2040.  Before any account is taken of 
evidence of EVT effectiveness in new sub populations of LAO stroke, this represents approximately 
an additional 2,400 to 4,900 LAO patients per annum eligible for thrombectomy.
DISCUSSION
Our updated analysis of the impact of new evidence between 2018-2021 on the numbers of patients 
in the UK eligible for EVT has shown that the addition of evidence from DAWN and DEFUSE 3 
resulted in a negligible impact on previous estimates of UK patients who are eligible for EVT.  Both 
trials increased the estimates of numbers of patients eligible in absolute terms only very modestly, 
mainly because of their strict eligibility criteria and because we had previously allowed for EVT 
eligibility up to 12h after onset (whether precise onset time known or not).  The shift of ASPECTS 
exclusion from <6 to <5 increased numbers eligible by a more substantial 5%. The inclusion of 
early presenting patients with moderate or severe strokes and a pre-stroke mRS of 3 or more 
increased annual eligibility as 3% fewer patients were deemed ineligible by this criterion.  
However, both increases were more than offset by a modest reduction in the assumed incidence of 
LAO (from 40 to 35%) due to new evidence 29 and a revision upwards in the proportion of early 
presenters with recanalisation before EVT could be performed (from 5 to 8.75%). In the UK, 
imaging practices may affect the observed LAO rate and the previous UK estimate of 39% may 
reflect a smaller denominator of patients 7.  

































































TESLA 14, TENSION 15, MOSTE 18, SELECT 2 16, LASTE 17 ENDOLOW 30 are amongst the 
ongoing trials whose results could appreciably alter our estimates form eligibility..  These trials 
have been taking place during the global COVID19 pandemic and completion and reporting of their 
results are likely to be delayed, potentially by up to 2 years, an additional justification to updating 
our 2017 eligibility estimates.  TESLA, estimated to complete at very earliest in late 2022, will 
consider patients with ASPECTS scores of 2-5 presenting within 24 hours of onset.  It therefore has 
the possibility to impact node G of our decision-tree (Clinical and CT exclusions in early 
presenters) and eligibility in late presenters identified by advanced Imaging (nodes H and M).  
Based on plausible ranges, such as the percentage of late presenters who had a pre-stroke mRS of 
three and would have favourable CTs, this indicates differences in eligibility of several hundred 
patients per year in the late-presenting group.  TENSION, now estimated to complete, at very 
earliest, in March 2024 includes patients with an ASPECTS score of 3-5 presenting within 11 hours 
and includes patients with low NIHSS scores as does ENDO-LOW trial.  These trials have the 
possibility to impact our estimates at nodes C, G and H.  Eligibility for EVT in patients with mild 
strokes (NIHSS <6) has the potential to considerably increase the eligible population by 5,820 at 
node D.  Assuming that this group of patients were equally likely to present early (78%) and 
becauselower NIHSS scores are likely to be associated with higher ASPECTS scores and mRS <3, 
the proportion of early presenters excluded at node G would decrease appreciably. However, it is 
probable that most of the low NIHSS early presenters would be lower (SSNAP reports 50% patients 
with mild strokes presenting within 270 minutes therefore of 5,820,  2,910 would still be eligible at 
point J).   Recent evidence also suggests benefits in patients with a pre-existing mRS of 3 (and 
above) further reducing clinical exclusions. Larsson and colleagues observed that 20% of patients 
with pre-stroke disability receiving EVT returned to their pre-stroke functional level 31.
SELECT 2, estimated to report at very earliest in early 2022, includes patients with an ASPECTS 
score of 3 or above within 24 hours of “last known well” and therefore has a similar potential to 
impact our estimates as TESLA (nodes G, H and M). LASTE, reporting at very earliest February 
2022, includes early presenters with an ASPECTS score of 0-5, or 4-5 if aged 80 or over.  The 
impact of LASTE is therefore at node G and node H.
Perhaps the most significant factor  to service planners though is the effect of an ageing population, 
which suggests numbers of stroke patients eligible for EVT increasing by >20% in 2030 and >40% 
in 2040. Ageing may be associated with poorer pre-stroke health but as there have been few 

































































participants aged 85+ in stroke EVT trials, the precise incidence of treatable LAO is unclear in this 
population. We also know that aging populations are increasing more in rural areas (generally living 
further away from urban EVT centres), resulting in later presentation on average.  
Our estimates take no account of cost effectiveness, which may influence decisions about eligibility 
for some groups with pre-existing disability or where EVT may reduce mortality in patients who 
survive with significant disability. 
CONCLUSION
The addition of new trial evidence from 2017-2021 has not substantially altered our previous 
estimate of stroke patients in the UK that are eligible for EVT each year.  Although ongoing trials 
have the prospect of further considerably revising estimates of overall eligibility (mostly increasing 
them), the Covid19 pandemic has delayed most of these trials appreciably and so our updated 
estimates and associated estimates of uncertainty are therefore an important source of information 
for those managing or commissioning EVT services in the next 2-3 years. Over a longer time 
horizon, population demographic trends appear to have the greatest impact on the incidence of LAO 
stroke and consequent demand for EVT services.
Figure Legends
Figure 1: Eligible Population (a; Total UK population including those deemed to be geographically 
inaccessible.  b: Confirmed infarcts, excluding ~2% of patients whose status is unconfirmed.  
Besides cerebral infarcts most acute subdural haematomas would also not be entered in to SSNAP 
nor SSCA. c: Includes basilar artery occlusions eligible for treatment if presenting within 12 hours.  
Others are assumed eligible unless they meet any subsequent exclusion. d: “Early presenters”- those 
presenting within licensed IVT window), late presenters or SUTO (4.5-12h or last known well up to 
12h ago) Note: Patients within the large lower grey shaded box are all dealt with by advanced 
imaging (8,250 + 1,330) those who are early presenters (8,250 on the left-hand side) can bypass that 
step.
Figure 2: Tornado diagram of one-way sensitivity analyses for key decision nodes
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8,690 + 1,330 = 10,020 (no AI early)
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40-64      342,712      336,897 131 0 0 449 441
65-74 958,520 1,316,576 509 0 0 4879 6,701
75-84   1,096,676   2,044,190 947 0 0 10,386 18,982
85-100 442,085  1,124,513 1823 5 10.5 8,462 22,652
Total 2,839,993 4,822,176 - - - 24,176 48,776
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N 8,690 Y 840
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4,720 + 3,510 = 8,230
A: CT Head Scan
Ischemic  Strokes Haemorrhagic Strokes
B: CT Angio




D: Known Time of
onset / Last seen well
> 12 hours or
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Y 1,264 + 69 = 1,330
8,690  (No AI Early )+1,330 =  10,020
to


























































































E: Time of Onset



















































































































































10,023 One Way Sensitivity Anayses
Number of strokes 2030 (119,600)
Number of strokes 2040 (144,300)
B.  LAO of Ischaemic Strokes (%) (30.0% 40.0%)
C. Inclusion of mild strokes (85%)
C. Inclusion of mild strokes (95%)
G. Clincal CT Exclusions Early Presenters (30%)
G. Clincal CT Exclusions Early Presenters (20%)
J.  Spontaneous recanalisation in early presenters (5.0% 10.0%)
H. Clinical CT Exclusions Late presenters (70%)
H. Clinical CT Exclusions Late presenters (65%)














Change in Eligible Patients
Low Estimate High Estimate
Advanced Imaging Pathway
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Node Description Point Low
Number of strokes 95500 119600
A Icheamic Strokes (%) 87.0% 86%
B LAO of Ischaemic Strokes (%) 35.0% 30%
C NIHSS >= 6 80.0% 85%
D KTO / LSW < 12 hours 78.0% 76%
E
Percentage of KTO / LSW Unknown time of
Onset 68.5% 65%
F Percentage of < 12 presenting early 74.0% 70%
G Clinical CT Exclusions Early Presenters 29.0% 30%
H Clinical CT Exclusions Late Presenters 72.5% 70%
I Advanced Imaging Exclusiuons Early Presenters 5.0% 3%
K Advanced Imaging Exclusiuons Late Presenters 43.0% 40%
J Spontaneous recanalisation in early presenters 8.8% 5%
L Spontaneous recanalisation in late presenters 2.0% 1%
M Presentations after 24hrs NIHSS > 6 LAO 11.5% 10%
N DAWN Eligibility in 12- 24hr presenters 5.0% 4%
One Way Sensitivity Anayses
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mRS > 2, ASPECTS < 6
Version 1
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5,390 + 4,010 = 9,400
A: CT Head Scan
Iscaemic Strokes Haemoragic Strokes
B: CT Angio
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onset / Last seen
well
> 12 hours or
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9,620  (No AI)
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A Icheamic Strokes (%)
B LAO of Ischaemic Strokes (%)
C NIHSS >= 6
D KTO / LSW < 12 hors
E
Percentage of KTO / LSW Unknown time of
Onset
F Percentage of < 12 presenting early
G Clinical CT Exclusions Early Presenters
H Clinical AI Exclusions Late Presenters
I Advanced Imaging Exclusiuons Early Presenters
K Advanced Imaging Exclusiuons Late Presenters
j Sponeaneous recalisation in early presenters
L Sponeaneous recalisation in late presenters
1,840> 12 
Hours
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